trial · primary record
Cyclophosphamide
Pediatric Osteosarcoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 41 |
| Primary completion | 2035-12 |
| Primary endpoint | Event-free survival (EFS), defined as time from SJCARB7H3-41BBL infusion to disease relapse, progressive disease, new systemic therapy, secondary malignancy or death |
| Registry ID | NCT07428993 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:11.218Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07428993
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cyclophosphamide · approval
- Cyclophosphamide · compound